CELL SOURCE INC.

Cell Source, Inc. is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Cell Source’s Veto Cell protocols are overcoming allogeneic transplantation’s greatest challenges, including the need to find donors, rejection, Graft vs. Host Disease, and life-threatening infections. Areas of Therapeutic Focus include: Stem Cell Transplantation (e.g. bone marrow transplantation), Cancer, Organ Transplants, and Non-Malignant Disease (Type-1 Diabetes, Sickle-cell Anemia, Multiple Sclerosis).